For the first time, Sun Pharmaceutical has seen its U.S. sales of innovative medicines overtake generics in the second quarter of FY26, marking a major shift for India’s largest drug maker. The surge came on the back of strong sales of Ilumya...
.png "Lupin's Pithampur Unit-3 Secures US FDA EIR Approval")
Lupin Limited, a global pharmaceutical company, has received the Establishment Inspection Report (EIR) of the Lupin Pithampur Unit-3 plant in Madhya Pradesh. This report is a follow-up to a successful inspection conducted between July 7 and...
Venus Remedies, one of the world’s top 10 manufacturers of fixed-dosage injectable drugs, has received new marketing authorizations in Vietnam for three key products methotrexate, cefuroxime, and irinotecan. These latest approvals strengthen the
Medicity, one of India’s premier super-speciality hospitals and Best Private Hospital in India, and it has unveiled its Advanced Surgical Heart Failure Clinic a state-of-the-art centre focused on the diagnosis, surgical treatment
Morgan Stanley PE-backed Omega Hospitals, based in Hyderabad, has successfully acquired Cytecare Hospitals, a prominent cancer care facility located in Bengaluru. This strategic acquisition signifies Omega's entry into a rapidly expanding
Cupid Ltd., a health and wellness products leading manufacturer, revealed that it foresees producing annual revenue of Rs 115 crore from the South African market, after its achievement of securing the largest allocation
Sun Pharmaceutical Industries Ltd has in Q2 of 2026 financial year, to a large extent, sold innovative medicines in the US market than generics. The achievement was a result of a robust market demand for Ilumya
The World Health Organization (WHO) and Bayer AG have renewed their two-decade collaboration to combat neglected tropical diseases (NTDs), extending the partnership through 2025–2030...
Zydus Lifesciences Limited has been provisionally granted by the US FDA to its 4mg Budesonide a delayed release capsule which is a move that would make the company broaden its market in the U.S. generics sector...
Ahmedabad-based Intas Pharmaceuticals has reinforced its position as a leading player in the Indian Pharmaceutical Market (IPM), maintaining the 6th rank for both September 2025 and the Moving Annual Turnover (MAT) period. The company reported...
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")